Personalized diabetes and cancer medicine: A rationale for anti-diabetic nutrition (Bitter Melon) in a supportive setting

Current Cancer Therapy Reviews

Volumn 8, Issue 1, 2012, Pages 66-77

  Zanker K S ^a   Mang, B ^b   Wolters, M ^b   Hahn, A ^b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Bitter melon; Cancer; Diabetes type 2; Dietary supportive care; Human clinical study; Momordica charantia L.; Personalized medicine; Prospective and doubleblinded

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CYTOCHROME P450 2D6; GEMCITABINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALTODEXTRIN; METFORMIN; MOMORDICA CHARANTIA EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TAMOXIFEN; VISCUM ALBUM EXTRACT;

ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CARBOHYDRATE METABOLISM; DIABETES CONTROL; DIABETIC DIET; DIABETIC PATIENT; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; DNA METHYLATION; DRUG EFFICACY; ETHNOPHARMACOLOGY; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; GLYCATION; GLYCOSYLATION; GOOD CLINICAL PRACTICE; HISTONE MODIFICATION; HUMAN; KINESIOTHERAPY; METABOLIC SYNDROME X; METASTASIS INHIBITION; MOMORDICA CHARANTIA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL SCIENCE; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; OXIDATIVE STRESS; PANCREAS CARCINOMA; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; TELOMERE HOMEOSTASIS; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

EID: 84857711122     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339412799462521     Document Type: Article

References (54)

1. Masur K, Thevenod F, Zänker KS. (eds.) Diabetes and Cancer: Epidemiological Evidence and Molecular Links. Frontiers in Diabetes (Porta M., Matschinsky F.M. series eds.), 2008; vol. 19: Karger AG, Publisher Basel, Switzerland.
2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60:207-21.
3. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674-85.
4. Dittmar T, Zänker KS, Schmidt A. (eds.) Infection and Inflammation. Impacts on Oncogenesis. Contribution to Microbiology (Schmidt A., Herwald H. series eds.), 2006; vol. 13, Karger AG Publisher Basel, Switzerland.
5. Hoggatt J. Personalized medicine - trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diag Ther 2011; 15: 53-5.
6. [Tian Q, Price ND, Hood L. Systems Cancer Medicine: Towards Realization of Predictive, Preventive, Personalized, and Participatory (P4) Medicine J Intern Med 2011; Dec 5: doi: 10.1111/j.1365-2796.2011.02498x (Epub ahead of print).
7. Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem 2011; 57:231-40.
8. Müller G. Personalized prognosis and diagnosis in type 2 diabetes - vision or fiction? Pharmacology 2010; 85:168-87.
9. Harper CC. Personalized medicine in diabetes: regulatory considerations. J Diabetes Sci. Technol 2009; 3:739-742.
10. Quinn CC, Shardell MD, Terrin ML, et al. Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care 2011; 34: 1934-42.
11. Greeley SA, John PM, Winn AN, et al. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care 2011; 34: 622-7.
12. Zaenker KS, Mihich E, Liu E. Personalized Cancer Medicine 2011. Towards individualized cancer treatments. XV International Fritz Bender Symposium held on February 21 to 23, 2011, at Matrix Biopolis, Singapore. Meeting Report/Brief Article, Transl. Oncology 2011; 4: 198-201.
13. Fenstermacher DA, Wenham RM, Rollison DE, et al. Implementing personalized medicine in a cancer center. Cancer J 2011; 17: 528-36.
14. Kucherlapati R. Introduction for: Frontiers of Personalized Cancer Medicine. Cancer J 2011; 17: 403-4.
15. [Keogh B. Era of Personalized Medicine May Herald End of Soaring Cancer Costs. J Natl Cancer Inst 2011; Dec 14 (Epub ahead of print).
16. De Souza JA, Olopade OI. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol 2011; 38: 263-73.
17. Sakuyama K, Sasaki T, Ujiie S, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18,27,36,39,47-51,53-55, and 57). Drug Metab. Dispos. 2008; 36: 2460-7.
18. Zanger UM, Tureinen M, Klein K. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 2008; 392: 1093-108.
19. Powe DP, Voss MJ, Zänker KS, et al. Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival. Oncotarget 2010; 1:628-38.
20. Ströhle A, Zänker KS, Hahn A. Nutrition in oncology: the case of micronutrients (review). Oncol Rep 2010; 24: 815-28.
21. Bozzett F. Nutritional supportive in oncologic patients: Where we are and where we are going. Clin Nutr 2011; 30: 714-7.
22. Paul F Diet, nutrition and telomore length. J Nutr Biochem 2011; 22: 895-901.
23. De Vere White R, Hackman RM, Kugelmass J. The dogmas of nutrition and cancer: time for a second (and maybe third) look. Ann NY Acad Sci 2010; 1190: 118-25.
24. Bälter K, Möller E, Fondell E. The effect of dietary guidelines on cancer risk and mortality. Curr Opinion Oncol 2012; 24: 90-102.
25. Choi SW, Friso S. Epigenetics: A new bridge between nutrition and health Adv Nutr (Bethesda) 2010; 1: 8-16.
26. [Verma M. Cancer Control and Prevention by Nutrition and Epigenetic Approaches. Antioxid Redox Signal 2011, Nov 3 (Epub ahead of print).
27. Niculescu MD, Lupu DS. Nutritional influence on epigenetics and effects on longevity. Curr Opin Clin Nutr Metab Care 2011; 14: 35-40.
28. Gullet NP, Ruhul Amin AR, Bavraktar S, et al. Cancer prevention with natural compounds. Semin Oncol 2010; 37: 258-81.
29. [Pearn J. On "officinalis" the names of plants as one enduring history of therapeutic medicine. Vesalius 2010; Suppl. 24-8.
30. Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal 2011; 3: 337-44.
31. De Luca LM, Norum KR. Scurvy and cloudberries: a chapter in the history of nutritional sciences. J Nutr 2011; 141: 2101-5.
32. N.N. (authors not listed) Developments in botanical dietary supplements research from 1994 to today in honor of Dr. Farnsworths 80th birthday. Proceedings of the 2010 DSHAE (Dietary Supplements Health and Education Act of 1994) Symposium. March 23, Chicago, Illinois, USA. Fitoterapia 2011; 82:1-91.
33. Martin DH. "Now we got lots to eat and they're telling us not to eat it": understanding changes to south-east Labrador Inuit relationships to food. Int J Circumpolar Health 2011; 70:384-395.
34. Leung L, Birtwhistle R, Kotecha J, et al. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr 2009; 102: 1703-8.
35. Fang EF, No TB. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med 2011; 11: 417-36.
36. Nerurka P, Ray RB. Bitter melon: antagonist to cancer. Pharm. Res. 2010; 27: 1049-53.
37. Nerurkar PV, Lee YK, Nerurkar VR. Momordia charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010; 10: 34.
38. Klomann SD, Mueller AS, Pallauf J. Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br J Nutr 2010; 104: 1613-20.
39. Nerurka PV, Johns LM, Buesa LM, et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation 2011; 8: 64.
40. Chaturvedi P, George S. Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food 2010; 13: 520-7.
41. Clouatre DL, Rao SN, Preuss HG. Bitter melon extracts in diabetic and normal rats favorably influence blood glucose and blood pressure regulation. J Med Food 2011;14:1496-504.
42. [Brennan VC, Wang CM, Yang WH. Bitter Melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidgenesis, and insulin-like growth factor type 1 receptor/RAC-alpha serine/ threonine protein kinase signaling. J Med Food 2011; Dec 22 (Epub ahead of print).
43. Pitchakam P, Suzuki S, Ogawa K, et al. Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantai leaf. Cancer Lett 2011; 306: 142-50.
44. Pitchakam P. Ogawa K, Suzuki S. Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci 2010; 101: 2234-40.
45. Ru P, Steele R, Nerurka PV, et al. Bitter Melon extract impairs prostate cancer cell cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev. Res. (Phila.) 2011; 4: 2122-30.
46. Pitchakam P, Ohnuma S, Pintha K, et al. Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)- mediated multidrug resistance. J Nutr Biochem 2012; 23:76-84.
47. Gadang V, Gilbert W, Hettiarchy N, et al. Dietary bitter melon seed increases peroxisome proliferator-activated receptor-gamma gene expression in adipose tissue, down-regulates the nuclear factor kappa B expression, and alleviates the symptoms associated with metabolic syndrome. J Med Food 2011; 14: 86-93.
48. [Koga H, Selvendiran K, Sivakumar R, et al. PPAR-gamma potentiates anticancer effects of gemcitabine on human pancreatic cancercells. Int. J. Oncol. 2011; Oct 20. doi:10.3892/ijo.2011.1237 (Epub ahead of print).
49. Matthes H, Friedel WE, Bock PR, et al. Molecular mistletoe therapy: Friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective, pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 2010; 10: 430-9.
50. [Fuangchan A, Sonthisombat P, Seubnukam T, et al. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J. Ethnopharmacol. 2011; 134: 422
51. Baur DM, Klotsche J, Hamnvik OP, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2011; 60: 1363-71.
52. Witter L. The blooming of the French lilac. J Clin Invest 2001; 108: 1105-7.
53. Bost F, Sahra IB, Marchand-Brustel Y, et al. Metformin and cancer therapy. Curr Opin Oncol 2012; 24: 103-8.
54. [Snee LS, Nerurkar VR, Dooley DA. Strategies to improve palatability and increase consumption intentions for Momordia charantia (bitter melon): a vegetable commonly used for diabetes management. Nutr. J. 2011; Jul 28; 10.78. doi 10.1186/1475-2891-10-78.